QuidelOrtho Corporation (NASDAQ:QDEL) Receives Consensus Rating of "Reduce" from Analysts

Key Points

• Analysts hold a bearish view of QuidelOrtho: Six analysts give the stock a consensus “Reduce” rating, including three sells and three holds. The average 12-month price target is $13.63, below the reported $14.74 share price.
• QuidelOrtho exceeded quarterly expectations, posting $0.13 in EPS versus the $0.05 loss analysts expected and revenue of $630.9 million versus $618.7 million. Revenue increased 2.8% year over year, although the company reported a negative net margin of 39.2%.
• Institutional investors and hedge funds own approximately 99% of QuidelOrtho’s shares, while the stock remains well below its 52-week high of $35.58 and has a market capitalization of about $1.01 billion.

QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report) has earned an average recommendation of "Reduce" from the six analysts that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell rating and three have issued a hold rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $13.6250.

QDEL has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on QuidelOrtho from $11.00 to $12.00 and gave the company an "underweight" rating in a research report on Wednesday, July 1st. UBS Group reissued a "neutral" rating and set a $12.00 target price on shares of QuidelOrtho in a report on Thursday, May 7th. Wall Street Zen upgraded QuidelOrtho from a "sell" rating to a "hold" rating in a research note on Sunday, June 28th. Zacks Research downgraded QuidelOrtho from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of QuidelOrtho in a research report on Friday, July 17th.

QuidelOrtho Stock Down 0.7%

Shares of QDEL stock opened at $14.74 on Friday. QuidelOrtho has a 52-week low of $9.92 and a 52-week high of $35.58. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -0.96 and a beta of 0.68. The firm's 50-day moving average is $15.82 and its 200-day moving average is $16.51. The company has a debt-to-equity ratio of 1.43, a quick ratio of 0.76 and a current ratio of 1.39.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.18. The business had revenue of $630.90 million during the quarter, compared to analysts' expectations of $618.72 million. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%.QuidelOrtho's quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the company posted $0.12 earnings per share. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Sell-side analysts predict that QuidelOrtho will post 0.75 EPS for the current year.

Institutional Trading of QuidelOrtho

A number of hedge funds have recently modified their holdings of the stock. Global Retirement Partners LLC lifted its position in QuidelOrtho by 3,691.7% during the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company's stock worth $26,000 after acquiring an additional 886 shares during the last quarter. Camelot Portfolios LLC acquired a new position in shares of QuidelOrtho in the fourth quarter valued at approximately $29,000. Hantz Financial Services Inc. grew its position in shares of QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company's stock valued at $31,000 after purchasing an additional 362 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of QuidelOrtho by 67.7% during the second quarter. GAMMA Investing LLC now owns 2,185 shares of the company's stock worth $38,000 after purchasing an additional 882 shares during the period. Finally, Larson Financial Group LLC increased its stake in shares of QuidelOrtho by 322.2% during the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company's stock worth $39,000 after purchasing an additional 1,015 shares during the period. Institutional investors and hedge funds own 99.00% of the company's stock.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company's product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source